Adam Veness Buys Shares of Dianthus Therapeutics, Inc. $DNTH
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Adam Veness, SVP, General Counsel and Sec. at Dianthus Therapeutics, Inc. ($DNTH), bought 30,000 shares at an average price of $17.88, for a total transaction of $536,400. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Dianthus Therapeutics, Inc. Stock Down 22.1%
Shares of Dianthus Therapeutics, Inc. ($DNTH) traded around $82.49 on Thursday, down 22.1% for the day.
Dianthus Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Get Dianthus Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DNTH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.